Ignite Creation Date:
2024-05-06 @ 7:28 PM
Last Modification Date:
2024-10-26 @ 3:07 PM
Study NCT ID:
NCT06027541
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-09-07
First Post:
2023-01-11
Brief Title:
Young Patients With Early Breast Cancer
Sponsor:
Peking Union Medical College Hospital
Organization:
Peking Union Medical College Hospital
Study Overview
Official Title:
Prospective Research of Young Patients With Early Breast Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The prognosis of young patients with breast cancer is relatively poor Chemotherapy damages ovarian function Endocrine treatment for up to 10 years delays the childbearing time of patients Treatment regimens in young breast cancer patients are still controversial in the following 1 Exemption from chemotherapy based on gene prediction results 2 Removing drugs that damage ovarian function from chemotherapy regimens 3 Giving ovarian protection drugs during chemotherapy for patients with hormone receptor HR 4 The right time to get pregnant In view of the above problems the treatment scheme recommended in the guidelines cannot meet the personalized needs of young breast cancer patients The project plans to establish a prognosis model for young patients with breast cancer and provide the patients hierarchical and refined management which is significant for prolonging survival time improving quality of life and protecting fertility This project plans to observe the relationship between the characteristics of immune genes pathological staging molecular typing treatment plans and prognosis in the cohort of young breast cancer patients and establish a young breast cancer prognosis model and verify it The project is expected to establish a prognosis model and provide a hierarchical and personalized precision treatment plan for young breast cancer patients so as to prolong the survival time improve the fertility rate and improve the quality of life
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None